The distribution of discordant HG cases in the different treatment subgroups was as follows: (P<0.05): 48 patients (38%) in adjuvant chemotherapy subgroup, 26 patients (18%) in hormone therapy subgroup, and 3 patients (12%) in no adjuvant treatment subgroup.
Currently, additional cohorts are being tested to provide sufficient number in the different treatment subgroups.
The proportion of responders was not significantly different between the two surgical subgroups (Table 2).
Estimates differed between treatment subgroups within trials; being highest in treatment subgroups assigned to psychosocial-based interventions.
This may reflect population differences between cohorts, different treatment regimes, or the limitations of sample size in our UK HIV-infected subgroup.
There existed no heterogeneity between two treatment subgroups (I = 12%).
Different distributions between subgroups could in part be responsible for different treatment effects, although the subgroups were selected according to the response criteria.
It is likely that patients have clearly defined preferences for treatments, both in terms of modality and general theoretical perspective and these preferences may differ between different subgroups of patients.
There were not differences between different subgroups.
To explore statistical HRQOL score differences between different subgroups, the Mann-Whitney-U-test was used.
